TNF and juvenile dermatomyositis: In severe JDM, 92% of the experts opted for initial therapy with MTX (15% oral, 77% subcutaneous), 62% for intravenous Immunoglobulins (IVIG), 56% for HCQ, 11% for AZA, 10% for rituximab (RTX), 8% for MMF, 7% for CSA, 5% for cyclophosphamide (CYC), 3% for TNF inhibition (TNFi) and 2% for tocilizumab (TCZ).